Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Naloxone (Primary)
- Indications Bulimia nervosa
- Focus Therapeutic Use
- Sponsors Opiant Pharmaceuticals
- 13 Oct 2017 According to an Opiant Pharmaceuticals media release, completion of enrollment is expected by the end of Q2 2018.
- 20 Mar 2017 According to an Opiant Pharmaceuticals media release, the company anticipates to report topline data from this study in the first half of 2018.
- 20 Mar 2017 Status changed from not yet recruiting to recruiting, according to an Opiant Pharmaceuticals media release.